Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites

Kitayama, Joji; Ishigami, Hironori; Yamaguchi, Hironori; Yamashita, Hiroharu; Emoto, Shigenobu; Kaisaki, Shoichi; Watanabe, Toshiaki

doi:10.1245/s10434-013-3208-y

Cited by 67 publications

(58 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another effort to use neoadjuvant intraperitoneal chemotherapy to control peritoneal metastases prior to gastrectomy was presented by Kitayama et al [59] . They used a combination of intraperitoneal and intravenous paclitaxel along with S-1.…”

Section: Results After Nipsmentioning

confidence: 99%

Gastric cancer: prevention and treatment of peritoneal metastases

Sugarbaker¹

2018

JCMT

View full text Add to dashboard Cite

Gastric cancer is an aggressive malignancy that may metastasize through the bloodstream to the liver, through lymphatics to regional lymph nodes, or by penetration of the peritoneal lining of the stomach to result in seeding of the abdominal and pelvis surfaces. Peritoneal metastases are the most common mode of cancer dissemination. Technologies to prevent or treat peritoneal metastases from advanced gastric cancer are presented in this manuscript. The world's literature, both recent and over the past three decades, was reviewed in order to identify publications that present information regarding gastric cancer peritoneal metastases. Over one dozen randomized controlled trials to test perioperative chemotherapy for prevention of peritoneal metastases were reviewed. All of the trials performed with regional chemotherapy during or shortly after gastrectomy were positive. The clinical data regarding the treatment of peritoneal metastases diagnosed at the time of primary cancer resection or in follow-up were reviewed. Neoadjuvant intraperitoneal and systemic chemotherapy shows that some long-term survivors occur after these treatments were combined with cytoreductive surgery and gastrectomy. Similar treatments are advocated for primary gastric cancer with cytology positive for gastric cancer but no visible implants. Surgery for gastric cancer should be combined with perioperative systemic and regional chemotherapy in order to maximally benefit patients with this disease by reducing the negative impact of peritoneal metastases on survival.

show abstract

Section: Results After Nipsmentioning

confidence: 99%

Gastric cancer: prevention and treatment of peritoneal metastases

Sugarbaker¹

2018

JCMT

View full text Add to dashboard Cite

show abstract

“…Other strategies for normothermic intraperitoneal chemotherapy long term for gastric cancer with peritoneal metastases Another approach to the concept of NIPEC-LT has been reported by Kitayama and colleagues [27]. They used oral S1 combined with intraperitoneal paclitaxel (20 Yet another approach to NIPEC-LT was reported by Fujiwara and coworkers [29].…”

Section: Results After Nipec-lt Plus Gastrectomy With Cytoreductionmentioning

confidence: 99%

Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview

Sugarbaker

2017

Pleura and Peritoneum

View full text Add to dashboard Cite

Background: Peritoneal metastases from gynecologic and gastrointestinal cancer is of increasing interest to surgical and medical oncologists because of newly recognized benefits of treatment. In contrast to prior outcomes, prolonged disease-free survival and cure have been reported. Methods: To date, the benefits are to use complete surgical removal of the peritoneal metastases combined with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered in the operating room. To supplement the local-regional control, normothermic intraperitoneal chemotherapy used long term (NIPEC-LT) and delivered by an intraperitoneal port has been explored. Results: In three high grade malignancies with the preponderance of cytoreductive surgery (CRS) and HIPEC treatment failures within the peritoneal space, NIPEC-LT has been favorably reported in the oncology literature. In ovarian cancer and malignant peritoneal mesothelioma the NIPEC-LT is used an adjuvant treatment in an attempt to preserve a surgical complete response of CRS. In gastric cancer, NIPEC-LT is given as a neoadjuvant treatment with responders going on to radical surgical resection. Responses are monitored by laparoscopy. Conclusions: This overview highlights benefits of NIPEC-LT in three diseases where benefits from CRS and HIPEC have been recognized but that local-regional failures persist. Improved results with NIPEC-LT have been reviewed for ovarian cancer, gastric cancer, and peritoneal mesothelioma.

show abstract

“…Thus far, PTX is considered to be the most suitable drug for IP chemotherapy, due to its prolonged retention time. In fact, recent clinical studies have suggested the usefulness of IP-PTX for peritoneal lesions in ovarian [36] or gastric [11,37] cancers. However, it remains unclear how deep the IP-PTX actually infiltrates into a tumor nodule on the peritoneal surface in these patients.…”

Section: Discussionmentioning

confidence: 99%

Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model

Kitayama

Ishigami

Yamaguchi

et al. 2017

Pleura and Peritoneum

Self Cite

View full text Add to dashboard Cite

Background: Repeated intraperitoneal (IP) administration of paclitaxel (PTX) with concurrent systemic chemotherapy is clinically effective for the treatment of peritoneal metastases (PM) from gastric cancer. However, it is unclear how biochemical modifications may affect the pharmacokinetics and bioavailability of IP administered PTX. Methods: In a xenograft PM model using human gastric cancer cells, MKN45, fluorescein-conjugated PTX (OG-PTX) was given IP and the intra-tumor distribution of PTX examined with fluorescein microscopy. Results: After IP injection, PTX was seen to directly infiltrate up to several hundred micrometers from the surface of the PM. Co-injection with 5 % non-animal stabilized hyaluronic acid increased PTX infiltration and suppressed the development of PM more efficiently than PTX alone. PTX solubilized with amphiphilic polymer composed of 2-methacryloyloxyethyl phosphorylcholine (MPC) and n-butyl methacrylate (BMA) efficiently formed a micellar formation 50-100 nm in diameter. IP injection of the nanomicellar PTX (PTX-30W) also showed significantly enhanced tumor infiltration and further inhibition of the growth of PM compared with PTX solubilized with Cremophor-ethanol (PTX-Cre). Finally, IP administration of NK105, another nanomicellar PTX, inhibited the growth of subcutaneous tumors as

show abstract

Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites

Abstract: Salvage gastrectomy after chemotherapy of S-1 with IV and IP PTX is promising, even for patients with highly advanced gastric cancer and severe peritoneal metastasis and malignant ascites.

Cited by 67 publications

References 29 publications

Gastric cancer: prevention and treatment of peritoneal metastases

Gastric cancer: prevention and treatment of peritoneal metastases

Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview

Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model

Contact Info

Product

Resources

About